Results 151 to 160 of about 25,234 (166)

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Lancet, The, 2011
Klemens Budde, Claudia Sommerer, Petra Reinke   +2 more
exaly  

SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

Lancet, The, 1999
Katherine Samaras, Donald J Chisholm
exaly  

Chapter 10: SGLT2 Inhibitors

2022
openaire   +1 more source

Dapagliflozin, an SGLT2 inhibitor, for diabetes

The Lancet, 2010
Markolf, Hanefeld, Thomas, Forst
openaire   +2 more sources

Hereditary angioedema with normal C1-inhibitor activity in women

Lancet, The, 2000
Konrad Bork
exaly  

Harnessing SGLT2 Inhibitors

JACC: Cardiovascular Imaging
openaire   +1 more source

Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial

Lancet, The, 2017
Marc A Riedl, Avner Reshef, Sladjana Andrejevic   +2 more
exaly  

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

Nature Reviews Drug Discovery, 2010
exaly  

HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATION

Lancet, The, 1977
exaly